These drugs belong to a class called GLP-1 receptor agonists , and while theyve helped many people see major results, they can also come with a big question mark: Will my insurance actually cover it
Compr Rev Food Sci F 19:759800
While generic versions won't appear immediately, more affordable options are expected in 2026
Certificate of Analysis available per production lot
GLP-1RAs have been correlated with a decreased risk of hepatic decompensation and liver cancer, with this protective effect being more significant in patients who do not have alcohol or tobacco use disorders as compared to those who do [42]
This is different from a compounded formula, which is not FDA approved and where little research currently exists surrounding safety and efficacy.53 Patients using compounded versions may not receive a standardized dose, and safety and efficacy data for these products is currently lacking